Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A "complement-ary" AIDS vaccine

M P Dierich1, H Stoiber, A Clivio

  • 1Institut für Hygiene and Ludwig Boltzmann Institut für AIDS-Forschung, Innsbruck, Austria.

Nature Medicine
|February 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thyroid dose guidance in elective supraclavicular breast radiotherapy: a national survey of practice patterns in Switzerland.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

The current practice of volumetric modulated arc therapy for breast cancer in Europe - A survey by the EFOMP VMAT breast working group.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2025
Same author

Evaluation of the prevalence of dental agenesis through the use of orthopantomography in a sample of subjects residing in Lombardy and Piedmont regions.

European journal of paediatric dentistry·2023
Same author

Evaluation of an aSi-EPID with flattening filter free beams: applicability to the GLAaS algorithm for portal dosimetry and first experience for pretreatment QA of RapidArc.

Medical physics·2013
Same author

Dosimetric evaluation of photon dose calculation under jaw and MLC shielding.

Medical physics·2013
Same author

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity.

Leukemia·2013
Same journal

Why high scores do not mean application readiness for health AI.

Nature medicine·2026
Same journal

Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.

Nature medicine·2026
Same journal

Biological aging might help to explain the rising risk of early-onset cancer.

Nature medicine·2026
Same journal

Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection.

Nature medicine·2026
Same journal

A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials.

Nature medicine·2026
Same journal

Blood-based circular RNAs for early diagnosis of Alzheimer's disease.

Nature medicine·2026
See all related articles

Human immunodeficiency virus (HIV) exploits the human complement system for its survival. This research explores the potential of a novel vaccine to disrupt this interaction and inhibit HIV.

Area of Science:

  • Immunology
  • Virology
  • Vaccine Development

Background:

  • The human complement system is a critical part of innate immunity.
  • Human immunodeficiency virus (HIV) has evolved mechanisms to evade immune responses.
  • HIV can hijack complement components for viral entry and immune evasion.

Purpose of the Study:

  • To investigate how HIV utilizes the human complement system.
  • To explore the feasibility of developing a vaccine targeting this interaction.
  • To determine if a vaccine can neutralize HIV's complement-mediated advantages.

Main Methods:

  • In vitro assays to study complement activation by HIV.
  • Analysis of complement component deposition on viral particles.
  • Testing vaccine-induced antibodies for complement-mediated neutralization of HIV.

Related Experiment Videos

  • Cell-based assays to assess viral infectivity in the presence of complement.

    • Main Results:

    • HIV actively recruits complement factors like C3 and C5.
    • Specific viral proteins are involved in complement system interaction.
    • Vaccine-induced antibodies can block complement deposition on HIV.
    • Antibodies targeting complement-interacting viral regions enhance complement-mediated viral clearance.

    Conclusions:

    • HIV's exploitation of the complement system is a key survival strategy.
    • Targeting these interactions with a vaccine offers a promising therapeutic avenue.
    • A complement-targeted HIV vaccine could enhance viral neutralization and reduce infectivity.